clevercast
{"PLE04":{"id":"25K6Em","session_id":"142","strictid":"PLE04","name":"142 PLE04 SCS","description":"Novel and outstanding scientific discoveries: Late Breakers","account_id":"VyXlrG","ts":1638882000},"SAT09":{"id":"WmoROG","session_id":"170","strictid":"SAT09","name":"170 SAT09","description":"Satellite Symposium","account_id":"VyXlrG","ts":1638875700},"LUN03":{"id":"VznJpk","session_id":"146","strictid":"LUN03","name":"146 LUN03","description":"Lunch","account_id":"VyXlrG","ts":1638875700},"SAT04":{"id":"ApYR49","session_id":"165","strictid":"SAT04","name":"165 SAT04","description":"Satellite Symposium","account_id":"VyXlrG","ts":1638869400},"SCS14":{"id":"2Mn0lD","session_id":"161","strictid":"SCS14","name":"161 SCS14","description":"Strategies for future Influenza and RSV disease vaccination","account_id":"VyXlrG","ts":1638862200},"SCS13":{"id":"AZzPe5","session_id":"160","strictid":"SCS13","name":"160 SCS13","description":"\u201cLong Covid\u201d: post and acute clinical sequelae of COVID-19","account_id":"VyXlrG","ts":1638862200},"SPI07":{"id":"AQ5erG","session_id":"141","strictid":"SPI07","name":"141 SPI07","description":"Pandemic Preparedness Planning in Peacetime","account_id":"VyXlrG","ts":1638862200},"COF05":{"id":"Wok6G7","session_id":"132","strictid":"COF05","name":"132 COF05","description":"Coffee Break","account_id":"VyXlrG","ts":1638860400},"PLE03":{"id":"Ak6zkJ","session_id":"129","strictid":"PLE03","name":"129 PLE03 SCS","description":"Plenary session dedicated to the work of Young Scientists","account_id":"VyXlrG","ts":1638856800},"FRW01":{"id":"WqYzQ3","session_id":"145","strictid":"FRW01","name":"145 FRW01","description":"Farewell Dinner","account_id":"VyXlrG","ts":1638813600},"SAT08":{"id":"27y3P5","session_id":"169","strictid":"SAT08","name":"169 SAT08","description":"Satellite Symposium","account_id":"VyXlrG","ts":1638806400},"SCS12":{"id":"2bzgbw","session_id":"159","strictid":"SCS12","name":"159 SCS12","description":"Viral and host factors in the transmission of influenza, RSV disease and Covid-19","account_id":"VyXlrG","ts":1638800100},"SCS11":{"id":"VPx46L","session_id":"158","strictid":"SCS11","name":"158 SCS11","description":"Human influenza, RSV disease and COVID-19 challenge studies","account_id":"VyXlrG","ts":1638800100},"SPI06":{"id":"AJr7Y4","session_id":"140","strictid":"SPI06","name":"140 SPI06","description":"Global health perspectives on acute respiratory virus disease and how to ensure an equitable response","account_id":"VyXlrG","ts":1638800100},"COF04":{"id":"WxzMYM","session_id":"131","strictid":"COF04","name":"131 COF04","description":"Coffee Break","account_id":"VyXlrG","ts":1638798300},"SCS10":{"id":"Ve0Mlz","session_id":"157","strictid":"SCS10","name":"157 SCS10","description":"Antiviral and immune therapy for influenza, RSV disease and COVID-19","account_id":"VyXlrG","ts":1638792000},"SCS09":{"id":"21a0qv","session_id":"156","strictid":"SCS09","name":"156 SCS09","description":"Viral and host factors in the pathogenesis of influenza, RSV disease","account_id":"VyXlrG","ts":1638792000},"SPI05":{"id":"2867Go","session_id":"139","strictid":"SPI05","name":"139 SPI05","description":"Risk assessment and risk communication in acute respiratory virus infections","account_id":"VyXlrG","ts":1638792000},"SAT07":{"id":"Vrywe3","session_id":"168","strictid":"SAT07","name":"168 SAT07","description":"Satellite Symposium","account_id":"VyXlrG","ts":1638786600},"LUN02":{"id":"2n8gwr","session_id":"133","strictid":"LUN02","name":"133 LUN02","description":"Lunch","account_id":"VyXlrG","ts":1638786600},"SCS08":{"id":"Wj0mp6","session_id":"155","strictid":"SCS08","name":"155 SCS08","description":"Pandemic threats from the animal world","account_id":"VyXlrG","ts":1638780300},"SCS07":{"id":"24a1kN","session_id":"154","strictid":"SCS07","name":"154 SCS07","description":"Lessons learned from and prospects for COVID-19 vaccination","account_id":"VyXlrG","ts":1638780300},"SPI04":{"id":"2OqeP6","session_id":"138","strictid":"SPI04","name":"138 SPI04","description":"Benefits of vaccinating healthcare workers and other risk groups","account_id":"VyXlrG","ts":1638780300},"COF03":{"id":"VyOMbZ","session_id":"130","strictid":"COF03","name":"130 COF03","description":"Coffee Break","account_id":"VyXlrG","ts":1638778500},"PLE02":{"id":"AKYoem","session_id":"171","strictid":"PLE02","name":"171 PLE02 KEY","description":"Plenary keynote lectures","account_id":"VyXlrG","ts":1638774900},"COM02":{"id":"V31qyx","session_id":"174","strictid":"COM02","name":"174 COM02","description":"Breakfast Company Lectures","account_id":"VyXlrG","ts":1638770400},"POS01":{"id":"VBXmr3","session_id":"144","strictid":"POS01","name":"144 POS01","description":"Poster Networking Session","account_id":"VyXlrG","ts":1638725400},"SAT06":{"id":"VyOMbw","session_id":"167","strictid":"SAT06","name":"167 SAT06","description":"Satellite Symposium","account_id":"VyXlrG","ts":1638720000},"SCS05":{"id":"AKYoex","session_id":"153","strictid":"SCS05","name":"153 SCS05","description":"Science based management of epidemics and pandemics","account_id":"VyXlrG","ts":1638713700},"SCS06":{"id":"V31qyY","session_id":"152","strictid":"SCS06","name":"152 SCS06","description":"Innate and adaptive immunity towards influenza, RSV disease and COVID-19","account_id":"VyXlrG","ts":1638713700},"SPI03":{"id":"VBXm1g","session_id":"128","strictid":"SPI03","name":"128 SPI03","description":"Diagnostic and Intervention strategies for the management of acute respiratory infections","account_id":"VyXlrG","ts":1638713700},"COF02":{"id":"VYez4d","session_id":"126","strictid":"COF02","name":"126 COF02","description":"Coffee Break","account_id":"VyXlrG","ts":1638711900},"SCS04":{"id":"VDrnvL","session_id":"151","strictid":"SCS04","name":"151 SCS04","description":"Co-infections in influenza, RSV disease and COVID-19","account_id":"VyXlrG","ts":1638705600},"SCS03":{"id":"W9m0ne","session_id":"150","strictid":"SCS03","name":"150 SCS03","description":"Diagnostic testing in the management of acute respiratory infections in primary and secondary care","account_id":"VyXlrG","ts":1638705600},"SPI02":{"id":"VvyLKk","session_id":"125","strictid":"SPI02","name":"125 SPI02","description":"Societal impact of influenza, RSV disease and COVID-19","account_id":"VyXlrG","ts":1638705600},"SAT05":{"id":"WwGzqx","session_id":"166","strictid":"SAT05","name":"166 SAT05","description":"Satellite Symposium","account_id":"VyXlrG","ts":1638700200},"LUN01":{"id":"2ave6y","session_id":"123","strictid":"LUN01","name":"123 LUN01","description":"Lunch","account_id":"VyXlrG","ts":1638700200},"SPI01":{"id":"A6n4jv","session_id":"53","strictid":"SPI01","name":"53 SPI01","description":"Why influenza and RSV disease are a priority for policy makers","account_id":"VyXlrG","ts":1638693900},"SCS02":{"id":"Wlq35K","session_id":"149","strictid":"SCS02","name":"149 SCS02","description":"Virus structure and replication in influenza virus, RSV and SARS-CoV-2; latest developments in influenza virus, SARS-CoV-2 and RSV molecular virology","account_id":"VyXlrG","ts":1638693900},"SCS01":{"id":"ALoxNq","session_id":"137","strictid":"SCS01","name":"137 SCS01","description":"Epidemiology, surveillance and modelling of influenza, RSV disease and COVID-19, including virus evolution and strain selection","account_id":"VyXlrG","ts":1638693900},"COF01":{"id":"AGZE95","session_id":"90","strictid":"COF01","name":"90 COF01","description":"Coffee Break","account_id":"VyXlrG","ts":1638692100},"PLE01":{"id":"AR1ody","session_id":"86","strictid":"PLE01","name":"86 PLE01 KEY","description":"Plenary keynote lectures","account_id":"VyXlrG","ts":1638688500},"COM01":{"id":"WdeNYe","session_id":"173","strictid":"COM01","name":"173 COM01","description":"Breakfast Company Lectures","account_id":"VyXlrG","ts":1638684000},"WEL01":{"id":"A0jDO7","session_id":"143","strictid":"WEL01","name":"143 WEL01","description":"Welcome reception","account_id":"VyXlrG","ts":1638639000},"CON01":{"id":"WNKe7v","session_id":"172","strictid":"CON01","name":"172 CON01","description":"Concert","account_id":"VyXlrG","ts":1638636300},"OPN01":{"id":"WEmYa4","session_id":"48","strictid":"OPN01","name":"48 OPN01","description":"Opening Ceremony","account_id":"VyXlrG","ts":1638632700},"SAT03":{"id":"WXZxdG","session_id":"164","strictid":"SAT03","name":"164 SAT03","description":"Satellite Symposium","account_id":"VyXlrG","ts":1638626400},"SAT02":{"id":"Wg0R69","session_id":"163","strictid":"SAT02","name":"163 SAT02","description":"Satellite Symposium","account_id":"VyXlrG","ts":1638620100},"SAT01":{"id":"25K6kz","session_id":"162","strictid":"SAT01","name":"162 SAT01","description":"Satellite Symposium","account_id":"VyXlrG","ts":1638613800}}
clevercast items
{"test":{"id":"Wdg7KX","session_id":"Lorem","strictid":"test","name":"Lorem test video","description":"Random test video","account_id":"VyXlrG","duration":"450"}}
Mon 6 Dec
Monday
6
December

Monday 6 December, 0830 - 0900 ET

Opening Session

Time:

Monday 6 December, 0830 - 0900 ET

  • Welcome Remarks, Amy Finan, Sabin Vacinne Institute
  • Welcome Remarks and Housekeeping Items, Denise Garrett, Sabin Vacinne Institute
  • Opening Keynote Address, Duncan Steele, Bill & Melinda Gates Foundation

Monday 6 December, 0900 - 1000 ET

Plenary Session

Time:

Monday 6 December, 0900 - 1000 ET

Track:

Typhoid Conjugate Vaccines in High-Burden Countries: where are we and where do we need to go?

Moderated by Rob Breiman, Emory University & Ashley Latimer, PATH

Kathleen Neuzil, University of Maryland, Baltimore

Adwoa Bentsi-Enchill, WHO

Emmanuel Mugisha, PATH

Francisco Luquero, GAVI

Monday 6 December, 1000 - 1015 ET

Break

Time:

Monday 6 December, 1000 - 1015 ET

Monday 6 December, 1015 - 1030 ET

Story Telling

Time:

Monday 6 December, 1015 - 1030 ET

  • Senjuti Saha, Child Health Research Foundation

Monday 6 December, 1030 - 1115 ET

Roundtable Discussion

Time:

Monday 6 December, 1030 - 1115 ET

Track:

Improving water and sanitation services in cities with endemic typhoid transmission

  • Steve Luby, Stanford University (Moderator)
  • Irene Nansubuga, National Water and Sewerage Corporation, Uganda
  • Barbara Evans, University of Leeds
  • Ranjiv Khush, Aquaya Institute

Monday 6 December, 1115 - 1130 ET

Break

Time:

Monday 6 December, 1115 - 1130 ET

Monday 6 December, 1130 - 1300 ET

Oral Abstracts

Time:

Monday 6 December, 1130 - 1300 ET

Track:

Cracking the Code: Developments in Genomics Research for Enteric Fever Control

Moderated by Christiane Dolececk, University of Oxford & Senjuti Saha, Child Health Research Foundation

  • OR100 - Using stem-cell derived gut organoids and macrophages to study transcriptomic response induced by S. Typhi and S. Paratyphi A infection in the human host, Emily Lees, University of Oxford/University of Cambridge
  • OR102 - Chromosomal integration of resistance mechanisms in ESBL-producing XDR Salmonella Typhi isolated from travellers returning to England and Wales from Pakistan, Satheesh Nair, Public Health England
  • OR105 - Impact of genome rearrangement in S. Typhi, Gemma Langridge, Quadram Institute Bioscience
  • OR106 - The origins of H58 Salmonella Typhi, Megan Carey, Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, UK
  • OR109 - Genomic analysis unveils the role of genetic changes in the emergence and persistence of S. Paratyphi A lineages, Agila Kumari Pragasam, Christian Medical College, Vellore
  • OR110 - Genomic Epidemiology of Salmonella Typhi underlines the significance of lineage resolution diagnosis, Balaji Veeraraghavan, Christian Medical College, Vellore

or

At the Bedside: Investigating Clinical Outcomes & Impact of Disease

  • OR101 - Complications and mortality of non-typhoidal Salmonella invasive disease: a global systematic review and meta-analysis, Christian Marchello, University of Otago
  • OR103 - Burden of Ileal Perforations in Surgical Patients Admitted in Hospitals of Three Asian countries:Surveillance of Enteric Fever in Asia Project (SEAP), 2016–2019, Saqib Hamid Qazi, Department of Surgery, Aga Khan University, Karachi, Pakistan
  • OR104 - Antimicrobial Resistance in Typhoidal Salmonella: Surveillance for Enteric Fever in Asia Project, 2016–2019, Farah Naz Qamar, Aga Khan University Hospital
  • OR107 - Emergency Detection of Salmonella Shedding in Malosa Typhoid Outbreak (replacing “PBMC signatures within 24 hours of infection associate with risk of developing acute typhoid fever, Peter Johnston, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield
  • OR108 - Typhoid Associated Terminal Illness Symptoms and End-of-Life Health Seeking Behaviour in Medically Underserved Communities in Rural, Southwestern Nigeria, Janet Ogundairo, Severe Typhoid in Africa (SETAPlus) Project Nigeria, Department of Medical Microbiology and Parasitology, College of Medicine, University of Ibadan, Ibadan, Nigeria
  • OR111 - Burden of Culture Confirmed Enteric Fever Cases in Karachi, Pakistan: Surveillance for Enteric Fever in Asia Project (SEAP), 2016–2019, Mohammad Tahir Yousafzai, Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan

Monday 6 December, 1300 - 2300 ET

Break

Time:

Monday 6 December, 1300 - 2300 ET

Monday 6 December, 2300 ET

Symposium Sessions

Time:

Monday 6 December, 2300 ET

Track:

Typhoid conjugate vaccine safety and efficacy: Results from clinical studies in Africa and Asia

Moderated by Kathleen Neuzil, University of Maryland, Baltimore

  • Efficacy of Typhoid Conjugate Vaccine in Children 9 Months to Under-16 Years in Nepal: A Participant-Observer-Blind Phase III Randomized Controlled Trial, Mila Shakya, Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Kathmandu, Nepal

  • Long-term efficacy of the typhoid conjugate vaccine in Malawi, Priyanka Patel, Malawi-Liverpool-Wellcome Trust Clinical Research Programme
  • Efficacy of Vi-Tetanus Toxoid Conjugate Vaccine (Vi-TT) in Bangladeshi Children: Results from an Interim Analysis of a Cluster-randomized Trial, Farhana Khanam, icddr, b
  • Effectiveness of Typbar® TCV against culture confirmed and extensively drug resistant typhoid among children in Hyderabad, Pakistan: a cohort study, Mohammad Tahir Yousafzai, Dept. of Pediatrics & Child Health, Aga Khan University

or

Diagnostics for Typhoid: Current status and future perspectives for product development and access

Moderated by Sabine Dittrich, FIND, Global Alliance for Diagnostics

  • Typhoid diagnosis from past to present: how far have we come? Buddha Basnyat, OUCRU-Nepal
  • The present: novel performance data of existing and commercially available POC tools from Africa and Asia, Jyotshna Sapkota, FIND; Nepal Medical College 
  • The future: Landscape of new developments and innovations, Stephen Baker, University of Cambridge
  • The reality of diagnosing typhoid in settings with limited laboratory capacity - particularly during a pandemic - Tamalee Roberts, Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit
  • Access challenges to better typhoid diagnostic-from quality to funding, Lee Hampton, GAVI, the Vaccine Alliance
Tue 7 Dec
Tuesday
7
December

Tuesday 7 December, 0000 - 0030 ET

Poster Session

Time:

Tuesday 7 December, 0000 - 0030 ET

Track:

  • P241 - Characterization of live attenuated Salmonella Typhimurium vaccines in infant mice, Nasrin Shamima, University of Maryland School of Medicine
  • P242 - Development of Antigen Microspot Arrays Based Immunoassay for Differential and Definitive Diagnosis of Typhoid Fever, Khairunnisa Abdul Lateef Khan, Advanced Medical and Dental Institute
  • P243 - O-antigen decorations in Salmonella enterica play a key role in the induction of functional immune responses against homologous and heterologous serovars, Francesca Micoli, GSK Vaccines Institute for Global Health
  • P244 - Rainfall contributes independently from P. falciparum malaria to non-typhoidal Salmonella bloodstream infections in hospital-admitted children in DR Congo, Bieke Tack, KU Leuven
  • P214 - Assessment of the diagnostic accuracy of rapid diagnostic tests for typhoid in Fiji and potential use for attribution of febrile illness outbreaks to typhoid, Aneley Getahun Strobel, Fiji National University, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Australia
  • P215 - Challenges of People Living with Typhoid Fever in Wukari Area of Taraba State, Nigeria, Pascal Ofiri, Kwararafa University Wukari
  • P216 - Changing pattern of clinical characteristics and antimicrobial susceptibility in children with Enteric fever at Dhulikhel Hospital, Nepal: A comparative study, Srijana Dongol, Kathmandu University Teaching Hospital
  • P217 - Development of Vi Polysaccharide Purification Technique As Component of Typhoid Vaccine: Effect Of Ethanol Washing To Impurity and Vi Polysaccharide, Dea Marsendah, PT Biofarma Indonesia
  • P218 - Genomic epidemiology of a cluster of XDR Salmonella Isangi at a tertiary hospital in Blantyre, Malawi using the MinION sequencer, Belson Kutambe, Malawi-Liverpool-Wellcome Trust Clinical Research Programme
  • P219 - Identification of Anti-Biofilm Entities against Salmonella enterica by Repositioning the Medicines for Malaria Venture’s Compound Libraries, Adeshola Adebayo Fagbemi, Department of Pharmaceutical Chemistry, University of Ibadan
  • P220 - Public Engagement during a Typhoid Conjugate Vaccine Trial in Lalitpur, Nepal, Ashata Dehal, Oxford University Clinical Research Unit- Nepal
  • P221 - Salmonella enterica from invasive bloodstream infections, water sources and poultry in rural Ghana- anthroponotic transmission? Denise Dekker, Bernhard Nocht Institute for Tropical Medicine
  • P222 - Salmonella Typhi epidemiology and evolution through a plasmid lens, Kaitlin Tagg, CDC
  • P223 - Surveillance of Typhoid Fever in a Typhoid Conjugate Vaccine trial in Nepal, Suchita Shrestha, Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Kathmandu, Nepal
  • P224 - The simultaneous emergence of multiple clades of Salmonella Typhi resistant to fluoroquinolones due to QRDR mutations in Blantyre, Malawi, Philip Ashton, Malawi-Liverpool-Wellcome Trust Clinical Research Programme

Tuesday 7 December, 0030 - 0200 ET

Oral Abstracts

Time:

Tuesday 7 December, 0030 - 0200 ET

Track:

Keep Your Guard Up: The Latest on Typhoid Vaccine Immunogenicity and Efficacy

Moderated by Melita Gordon, University of Liverpool & Justin Im, IVI

  • OR128 - Efficacy of Typhoid Conjugate Vaccine in Nepal: A Participant-Observer-Blind Phase III Randomized Controlled Trial, Mila Shakya, Oxford University Clinical Research Unit - Nepal, Patan Academy of Health Sciences, Lalitpur, Nepal
  • OR131 - Immunogenicity of Typhoid Conjugate Vaccine in Nepal: A Participant-Observer-Blind Phase III Randomized Controlled Trial, Mila Shakya, Oxford University Clinical Research Unit - Nepal, Patan Academy of Health Sciences, Lalitpur, Nepal
  • OR112 - Protection by Vaccination of Children against Typhoid Fever with a Vi-Tetanus Toxoid Conjugate Vaccine (Vi-TT) in Urban Bangladesh: A Cluster-Randomized Trial, John D. Clemens, icddr, b
  • OR114 - Immune responses induced in children after vaccination with Vi-TT vaccine: immunogenicity data from a cluster-randomised controlled trial in Bangladesh, Firdausi  Qadri, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh
  • OR116 - A phase IV, randomized, open-label, immunogenicity and safety trial of Typbar-TCV™ and Typhim Vi® in healthy children, Vinay Kumar Aileni, Bharat Biotech International Limited
  • OR118 - Serologic response using ELISA anti-Vi IgG antibodies at several time points following a single shot of Typbar-TCV among HIV children in Larkana, Pakistan, Rabab Batool, Aga Khan University Hospital

or

Keeping a Watchful Eye: Exploring Surveillance for Enteric Fever

Moderated by Andrea Haselbeck, IVI & Farah Naz Qamar, The Aga Khan University

  • OR127 - TyphiNET: An online dashboard for global genomic surveillance of Salmonella Typhi, Zoe Dyson, London School of Hygiene and Tropical Medicine
  • OR132 - School-based Rapid Assessment of Enteric Fever in Lyari Town, Karachi: Surveillance of Enteric Fever in Asia Project, Irum Fatima, Aga Khan University, Karachi, Pakistan
  • OR113 - Paratype: A genomic surveillance framework and an open-source tool for Salmonella Paratyphi A, Arif Mohammad Tanmoy, Child Health Research Foundation
  • OR115 - Seroprevalence of Salmonella typhi and fluroquinolones resistant gene characterization in southwest Nigeria, Jessica Uwanibe
  • OR117 - The impact of the community and public health response to COVID-19 on Typhoid surveillance and detection in Malawi, Priyanka Patel, Malawi-Liverpool-Wellcome Trust Clinical Research Programme
  • OR135 - The development of a multiplex immunoassay to screen 30,000 serum samples to measure the burden of Typhoid fever: The STRATAA sero-epidemiology study, Paula Russell, Cambridge University

Tuesday 7 December, 0800 - 0900 ET

Workshop

Time:

Tuesday 7 December, 0800 - 0900 ET

Track:

Universal Challenges, Shared solutions: A discussion about how we take on typhoid together

Moderator: Farzana Muhib, PATH

Millions vaccinated and millions to go: TCV campaign challenges, solutions, and the pathway forward in Pakistan - M. Imran Khan, PHC global (pvt). Ltd.

Leading the way with TCV in Africa; shared lessons for upcoming campaign introductions - Alice O. Peter, EPI Consultant (Liberia)

Integrated TCV campaign in Zimbabwe: what we know now – Jessica Farley, PATH

Tuesday 7 December, 0900 - 1000 ET

Symposium Sessions

Time:

Tuesday 7 December, 0900 - 1000 ET

Track:

Sero-epidemiology of enteric fever: Rapidly assess disease burden to inform vaccine introduction

Moderators: Jessica Seidman, Sabin Vaccine Institute & Jason Andrews, Stanford University

  • Diagnostic accuracy of HlyE and LPS for distinguishing enteric fever from other acute fever etiologies, Richelle Charles, Massachusetts General Hospital
  • Leveraging longitudinal antibody kinetics to derive enteric fever incidence estimates in population-based samples, Kristen Aiemjoy, Stanford University
  • Using sero-epi to generate granular sub-national data: Comparing Dhaka, Mirzapur, and Chittagong, Sira Jam Munira, Child Health Research Foundation
  • Using sero-surveillance to identify risk factors for enteric fever, Dipesh Tamrakar, Dhulikhel Hospital, Kathmandu Medical College

or

What should we be recommending for the treatment of enteric fever?

Moderated by Christopher M. Parry, Liverpool School of Tropical Medicine and Buddha Basnyat, OUCRU-Nepal

  • How strong is the evidence for current treatment regimens for acute enteric fever? Christopher Parry, Liverpool School of Tropical Medicine, Liverpool, UK 
  • What are the treatment options for XDR typhoid and should we use steroids in severe disease? Farah Qamar, Aga Khan University Hospital, Karachi, Pakistan
  • Should we combine antimicrobials to treat enteric fever? The ACT-South Asia Trial, Samita Rijal; OUCRU-Nepal, Kathmandu, Nepal
  • How should we treat a patient with chronic typhoid faecal carriage? Naina McCann; Hospital for Tropical Diseases, UCL, London, UK
  • Emerging resistance patterns and potential new treatments. Any hope on the horizon?Stephen Baker, Department of Medicine, University of Cambridge, UK

Tuesday 7 December, 1000 - 1030 ET

Poster Session

Time:

Tuesday 7 December, 1000 - 1030 ET

Track:

  • P240 - Extended anti-Vi IgG responses in 15-month-old children vaccinated with a typhoid conjugate vaccine in Burkina Faso, Alphonse Ouedraogo, Groupe de Recherche Action en Santé (GRAS)
  • P200 - Burden of Enteric Fever related Mortality in Karachi, Pakistan, 2016 – 2020, Sonia Qureshi, Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan
  • P201 - Isolation of S. Typhi from River water and environmental surveillance within Blantyre, Malawi, Jonathan Rigby, Liverpool School of Tropical Medicine
  • P202 - A Phase IV Study to Evaluate the Immunogenicity and Safety of Purified Vi capsular polysaccharide tetanus toxoid conjugate vaccine; Typbar-TCV® in Adults, Ashwini Maratha, Bharat Biotech International Limited
  • P203 - Assessment of a rapid diagnostic test for typhoid fever, Sabina Dongol, Patan Academy of Health Sciences, Nepal
  • P204 - Coverage Survey of Typhoid Conjugate Vaccine (TCV) among children 6 months to 15 years of age in an urban slum settlement of Lyari Town Karachi, Pakistan, Rabab Batool, Aga Khan University Hospital
  • P205 - Factors associated with incidence of Enteric Fever in a Paediatric Cohort in North India, Nonita Dudeja, Centre for Health Research and Development, Society for Applied Studies, New Delhi, India
  • P206 - Genomic surveillance of Invasive Salmonella in Southwest Nigeria, Afolayan Ayorinde, Global Health Research Unit on Genomic Surveillance of Antimicrobial Resistance, Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Ibadan, Oyo State, Nigeria.
  • P207 - Investigating the role of the meat pathway in nontyphoidal salmonellosis in East Africa, Kate Thomas, University of Otago
  • P208 - Is blood culture for pathogen recovery from febrile patients worthwhile when patients are antimicrobrial pretreated or cannot supply recommended blood volumes? Oyeniyi Stephen Bejide, Department of Medical Microbiology & Parasitology, College of Medicine, University of Ibadan
  • P209 - Molecular Detection of Salmonella Typhi and Paratyphi A with Genomic Markers of Resistance, Fahad Khokhar, University of Cambridge
  • P210 - Risk factors associated with the extensively drug-resistant (XDR) typhoid in an outbreak setting of Lyari Town Karachi, Pakistan, Rabab Batool, Aga Khan University Hospital
  • P211 - Safety of a novel typhoid conjugate vaccine in HIV-exposed uninfected Malawian infants, Nginache Nampota-Nkomba, Blantyre Malaria Project, University of Malawi
  • P212 - The Azithromycin and Cefixime treatment of typhoid in South Asia Trial (ACT-South Asia trial), Samita Rijal, Oxford University Clinical Research Unit-Nepal
  • P213 - Typhoid Fever outbreak in Neno District, Malawi: Lessons learnt from the routine data collected, Moses Aron, Partners In Health/Abwenzi Pa Za Umoyo

Tuesday 7 December, 1030 - 1115 ET

Roundtable Discussion

Time:

Tuesday 7 December, 1030 - 1115 ET

Track:

Nontyphoidal Salmonella Invasive Disease: Challenges and Solutions?

  • John Crump, University of Otago (Moderator)
  • Melita A. Gordon, Malawi Liverpool Wellcome Trust Programme and University of Liverpool
  • Samuel M. Kariuki, Kenya Medical Research Institute
  • Tonney S. Nyirenda, University of Malawi
  • Lisette Mbuyi, University Hospital of Kinshasa
  • Ellis Owusu-Dabo, Kwame Nkrumah University of Science and Technology
  • Marie-France Phoba, University Hospital of Kinshasa
  • James A. Platts-Mills, University of Virginia
  • Bieke Tack, Institute of Tropical Medicine Antwerp, Belgium

Tuesday 7 December, 1115 - 1130 ET

Break

Time:

Tuesday 7 December, 1115 - 1130 ET

Tuesday 7 December, 1130 - 1300 ET

Oral Abstracts

Time:

Tuesday 7 December, 1130 - 1300 ET

Track:

I Can See the Light: Breaking Down the Impact & Effectiveness of the Typhoid Conjugate Vaccine

Moderated by Aziza Mwisongo, PATH & Jacob John, Christian Medical College Vellore

  • OR120 - Serological response using ELISA Anti-Vi-IgG after single dose of Typhoid Conjugate Vaccine against Salmonella Typhi among children in Hyderabad, Pakistan, Sonia Qureshi, Aga Khan University Hospital
  • OR121 - Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: A case-control study, Rabab Batool, Aga Khan University Hospital
  • OR123 - Impact of mass vaccination with the new typhoid conjugate vaccine on Salmonella Typhi incidence in Harare, Zimbabwe, Ioana Diana Olaru, London School of Hygiene and Tropical Medicine, UK; Biomedical Research and Training Institute, Zimbabwe
  • OR125 - Serious adverse events in a typhoid conjugate vaccine efficacy study in Malawi, Priyanka Patel, Malawi-Liverpool-Wellcome Trust Clinical Research Programme
  • OR130 - Effectiveness of Typhoid Conjugate Vaccine against culture-confirmed S. Typhi among children aged 9 months to 15 years in Sindh, Pakistan, Rozina Thobani, Aga Khan University, Karachi
  • OR134 - Typhoid Conjugate Vaccine and Japanese Encephalitis Vaccine used in pregnancy: a case series, Katherine Theiss-Nyland, Oxford Vaccine Group, University of Oxford

or

WASH and Beyond: Enteric fever and the Environment

Moderated by Jay Bhagwan, Water Research Commission South Africa & Daniele Lantagne, Tufts University

  • OR119 - Prevention of typhoid fever by existing improvements of WASH and Vi polysaccharide typhoid vaccine in poor urban slums. Results from a cluster-randomized trial, Justin Im, International Vaccine Institute
  • OR122 - Microbial ecology insights from watershed to laboratory on S. Typhi persistence in the environment, Aaron Jenkins, University of Sydney, Edith Cowan University, Fiji Centre for Communicable Disease
  • OR124 - Assessment of Potential Typhoid and Paratyphoid Environmental Transmission Pathways for Adults and Children in Kolkata, India, Yuke Wang, Center of Global Safe WASH, Emory University
  • OR126 - Environmental surveillance for typhoidal Salmonellas in household and surface waters in Nepal identifies potential transmission pathways, Sneha Shrestha & Christopher Leboa, Stanford University
  • OR129 - Better Existing WASH is Associated with a Reduced Risk of Typhoid in Urban Slums: Results from a Prospective Cohort Study from Bangladesh, Birkneh Tadesse, International Vaccine Institute
  • OR133 - Wastewater-based environmental surveillance of enteric fever in Kolkata, India, Renuka Kapoor, Emory University

Tuesday 7 December, 1300 - 2300 ET

Break

Time:

Tuesday 7 December, 1300 - 2300 ET

Tuesday 7 December, 2300 ET

Plenary Session

Time:

Tuesday 7 December, 2300 ET

Track:

Impact of COVID-19 on Research and Immunization Programs

Moderated by Isaac Bogoch, University of Toronto & Kirsten Vannice, Bill & Melinda Gates Foundation

Gagandeep (Cherry) Kang, Christian Medical College

Soofia Yunus, EPI Pakistan

Amol Chaudhari, CEPI

Isaac Bogoch, University of Toronto

Wed 8 Dec
Wednesday
8
December

Wednesday 8 December, 0000 - 0015 ET

Story Telling

Time:

Wednesday 8 December, 0000 - 0015 ET

Front-line workers to the front - Stories from Pakistan

  • Habib Afsar and Imran Nafees, Precision Health Consultants Global

Wednesday 8 December, 0015 - 0030 ET

Break

Time:

Wednesday 8 December, 0015 - 0030 ET

Wednesday 8 December, 0030 - 0200 ET

Oral Abstracts

Time:

Wednesday 8 December, 0030 - 0200 ET

Track:

Driving Ahead of the Curve: A Glimpse into What's Next for Vaccine Development

Moderated by Sam Kariuki, Kenya Medical Research Institute  & Sushant Sahastrabuddhe, IVI

  • OR153 - MAPS vaccine against Salmonella enterica serovars Typhimurium and Enteritidis, Yingjie Lu, Boston Children
  • OR157 - Safety & immunogenicity of typhoid conjugate vaccine co-administration w routine 9 & 15 month vaccination in Burkina Faso: A randomized controlled phase 2 trial, Alphonse Ouedraogo, Groupe de Recherche Action en Santé (GRAS)
  • OR136 - Safety and long-term immunogenicity of a novel typhoid conjugate vaccine in Malawian infants and children, Nginache Nampota-Nkomba, Blantyre Malaria Project, University of Malawi
  • OR138 - An effective, affordable and sustainable vaccine to tackle Salmonella disease in sub-Saharan Africa, Rocio Canals Alvarez, GSK Vaccines Institute for Global Health
  • OR140 - Antibody-dependent neutrophil phagocytosis associates with distinct antibody glycosylation profiles following typhoid vaccination, Mari Johnson, Oxford Vaccine Group
  • OR142 - Phase 1 Trial of a Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Non-typhoidal Salmonella Infections and Typhoid Fever in sub-Saharan Africa, Myron Levine, Center for Vaccine Development and Global Health, University of Maryland School of Medicine

or

Pieces of a Puzzle: iNTS: Research Round-up

Moderated by Nick Feasey, Liverpool School of Tropical Medicine,  &  Ellis Owusu-Dabo, Kwame Nkrumah University of Science and Technology

  • OR152 - Antimicrobial resistance and sickle cell protein analysis in non-typhoidal Salmonella from children below 16 years in informal settlements in Nairobi, Kenya, Susan Kavai, STRATAA
  • OR155 - Incidence and associated mortality of invasive non-typhoidal Salmonella in Mozambican children admitted to the Manhiça District Hospital, Inacio Mandomando, Centro de Investigação em Saúde de Manhiça
  • OR137 - A different toolbox: isolation and characterisation of bacteriophages with activity against multidrug resistant invasive non-typhoidal Salmonella, Blanca Perez-Sepulveda, University of Liverpool
  • OR139 - Sero-epidemiology in Africa of invasive non-typhoidal salmonellosis (SAiNTS study); study aims, design and early findings, Helen Dale, University of Liverpool 
  • OR156 - Incidence of non-typhoidal Salmonella invasive disease: a systematic review and meta-analysis, Christian Marchello, University of Otago
  • OR141 - Peripheral and duodenal gamma-delta T cells show impaired functional responses to Salmonella Typhimurium in people living with HIV, Ndaru Jambo, University of Liverpool

Wednesday 8 December, 0800 - 0900 ET

Workshop

Time:

Wednesday 8 December, 0800 - 0900 ET

Track:

Supportive Resources for Genomic Data Generation, Analysis & Visualization

  • Megan Carey, Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, UK
  • Sofonias Tessema, Africa Centers for Disease Control and Prevention (Africa CDC): Africa Pathogen Genomics Initiative
  • Iruka Okeke, University of Ibadan
  • Silvia Argimón, Centre for Genomic Pathogen Surveillance, Big Data Institute, University of Oxford
  • Zoe Dyson, London School of Hygiene & Tropical Medicine, Monash University, University of Cambridge, Wellcome Sanger Insitute
  • Kat Holt, London School of Hygiene & Tropical Medicine, Monash University
  • Stephen Baker, University of Cambridge

Wednesday 8 December, 0900 - 1000 ET

Symposium Sessions

Time:

Wednesday 8 December, 0900 - 1000 ET

Track:

Typhoid Fever in WHO Eastern Mediterranean Region: Characterizing occurrence, antimicrobial resistance, and national surveillance and vaccine recommendations

Moderated by Evans Buliva, WHO, EMRO

  • Overview of Typhoid Fever in the WHO Eastern Mediterranean Region: Surveillance and Vaccine Recommendations, Muhammad Tayyab, WHO, EMRO
  • Typhoid Fever in the Eastern Mediterranean Region, 1990–2019: A Systematic Literature Review, Grace D. Appiah, CDC
  • Typhoid Fever in the Middle East and North Africa Region: Laboratory Surveillance of Isolates, Antoine Abou Fayad, American University of Beirut
  • Typhoid Fever associated with travel to the WHO Eastern Mediterranean Region: Epidemiology and Antimicrobial Resistance – US, 2016-2020, Kaitlin Tagg, CDC
  • Typhoid fever conference wrap up and next steps, Abubakar Abdinasir, EHO, EMRO

or

Typhoid intestinal perforations in Africa: What do we know? What can we learn?

Moderated by Kathleen Neuzil, University of Maryland, Baltimore

  • Typhoid intestinal perforations in Africa, an overview, Megan Birkhold, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Complications and mortality of typhoid fever: A global systematic review and meta-analysis, Christian Marchello, University of Otago, Dunedin, New Zealand 
  • Characterization of typhoid intestinal perforation in Africa: Results from the Severe Typhoid Fever Surveillance in Africa (SETA) program, Kayode Ogundoyin, Department of Surgery, College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria
  • Typhoid fever complications in rural Niger, Katherine Shafer, Hôpital de la SIM Galmi/Pan-African Academy of Christian Surgeons General Surgery Residency Program - Niger

or

Typhoid conjugate vaccines introduction: comprehensive new tools, processes, and findings for decision-making

Moderated by Aziza Mwisongo, PATH

  • Typhoid data in the early adopter countries, Lassane Kabore, PATH
  • BRAT -  The framework and tool for typhoid burden and risk assessment, Lucy Breakwell, USCDC
  • The cost of typhoid fever, data and implications for TCV decision-making in Malawi, Fumbani Limani, University of Malawi
  • Estimating the cost to deliver TCV, current support and data, Rouden E Mkisi, PATH

Wednesday 8 December, 1000 - 1030 ET

Poster Session

Time:

Wednesday 8 December, 1000 - 1030 ET

Track:

  • P225 - A simple clinical score combined with a rapid diagnostic test for the diagnosis of enteric fever, Christopher M. Parry, Liverpool School of Tropical Medicine
  • P226 - An outbreak of Salmonella Paratyphi A in Vadodara, India, in 2018, Joana Pereira-Dias, University of Cambridge
  • P227 - Analysis of an IncHI2 plasmid conferring an Extensively Drug-Resistant phenotype to Salmonella Isangi from a nosocomial outbreak in Blantyre, Malawi, Happy Banda, Malawi-Liverpool-Wellcome Trust Clinical Research Programme
  • P228 - Antigenic variation in Salmonella Paratyphi A – implications for immunological responses and vaccine design, Elli Mylona, University of Cambridge
  • P230 - Detection of Salmonella Enterica species in drinking water sources- Surveillance of Enteric Fever in Asia Project (SEAP) study, 2019 - 2020, Irum Fatima, Aga Khan University Hospital
  • P231 - Effects of Age and Sex on the Immune Response to Typhoid Conjugate Vaccine in a Phase III Randomized Controlled Trial in Nepal, Mila Shakya, Oxford University Clinical Research Unit - Nepal, Patan Academy of Health Sciences, Lalitpur, Nepal
  • P232 - Evolutionary insights and clinical observations of Salmonella Enteritidis causing Invasive Nontyphoidal Salmonellosis in India, Jobin John Jacob, Christian Medical College, Vellore
  • P233 - Immune responses to typhoid conjugate vaccine among children less than two years of age in Nepal: a study protocol, Sanjeev Bijukchhe, Patan Academy of Health Sciences
  • P234 - Multiple drug resistant Non-typhoidal Salmonella (NTS) bacteremia and other NTS isolates from different sources in Lagos, Nigeria, Kabiru Akinyemi, Lagos State University
  • P235 - Non-Expert Point-Of-Care Ultrasound Demonstrates High Sensitivity/Specificity In Detecting Gallstones: Data From The Samoa Typhoid Fever Surveillance Initiative, Seth Hoffman, Division of Infectious Diseases & Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
  • P236 - Patient characteristics and geo-spatial distribution of typhoid intestinal perforation in Ibadan; a retrospective review from 2012-2016, Titus Ebo, University of Ibadan
  • P237 - Salmonella Enteritidis from human clinical samples: Invasive diseases, Sujatha Pathirage, Medical Research Institute
  • P238 - Serum bactericidal antibodies after exposure to Salmonella Paratyphi A in an experimental controlled human infection model, Elizabeth Jones, Oxford Vaccine Group
  • P239 - Typhoid fever among health workers linked to community outbreak: role of whole genome sequencing to complement epidemiological data in outbreak investigation - Aneley Getahun Strobel, Fiji National University, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Australia.

Wednesday 8 December, 1030 - 1115 ET

Roundtable Discussion

Time:

Wednesday 8 December, 1030 - 1115 ET

Track:

Typhoid Elimination: Challenges and Opportunities

  • Supriya Kumar, Bill & Melinda Gates Foundation (Moderator)
  • Raphael Zellweger, IVI
  • Yaw Adu-Sarkodie, KNUST
  • Firdausi Qadri, isddr,b
  • Samantha Vanderslott, Oxford Vaccine Group

Wednesday 8 December, 1115 - 1130 ET

Break

Time:

Wednesday 8 December, 1115 - 1130 ET

Wednesday 8 December, 1130 - 1300 ET

Oral Abstracts

Time:

Wednesday 8 December, 1130 - 1300 ET

Track:

Dig a Little Deeper: A Look into Genomics for Enteric Fever Surveillance

Moderated by Stephen Baker, University of Cambridge & Arif Tanmoy, Child Health Research Foundation

  • OR143 - Genomic analysis of S. Typhi in Colombia, Diaz Guevara & Paula Lucia, Instituto Nacional de Salud, Colombia
  • OR145 - The Strategic Typhoid Alliance Across Africa and Asia (STRATAA): Genetic epidemiology of typhoidal Salmonella in Blantyre, Kathmandu and Dhaka, Zoe Dyson, London School of Hygiene and Tropical Medicine
  • OR147 - Phylogenomics and antimicrobial resistance of Salmonella Typhi and Paratyphi A, B & C in England, 2016-2019, Marie Chattaway, Public Health England
  • OR149 - Emergence and international spread of antimicrobial-resistant Salmonella Typhi, Kesia da Silva, Stanford University
  • OR154 - Historic (1980s) and recent Salmonella Typhi genotypes in Santiago, Chile, Mailis Maes, Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, UK
  • OR159 - Combined phylogenomic, epidemiologic, and geospatial cluster analyses to understand endemic typhoid fever transmission in Samoa, Michael Sikorski, Department of Microbiology and Immunology, University of Maryland School of Medicine

or

The Price We Pay: Understanding Cost and Policy in Decision Making for Vaccine Introduction

Moderated by Jillian Gauld, Institute for Disease Modeling & Clint Pecenka, PATH

  • OR144 - Cost of illness due to severe enteric fever in India, Dilesh Kumar, Christian Medical College, Vellore
  • OR146 - Evaluating the short and medium term impact of enteric fever on families in Nepal: Results from the TyVAC Cost of Illness Study, Amanda Schulhofer, Johns Hopkins Bloomberg School of Public Health
  • OR148 - Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting, Virginia Pitzer, Yale School of Public Health
  • OR150 - Gavi funding partnership: Typhoid conjugate vaccine introduction in Malawi, Priyanka Patel, Malawi-Liverpool-Wellcome Trust Clinical Research Programme
  • OR151 - Comparison of model predictions of typhoid conjugate vaccine impact and cost-effectiveness, Holly Burrows, Yale University
  • OR158 - Perspectives of typhoid fever and perceptions of typhoid vaccine towards shaping the decision to vaccinate, Sangwani Salimu, Malawi Liverpool Wellcome Trust Clinical Research Programme

Wednesday 8 December, 1300 - 2245 ET

Break

Time:

Wednesday 8 December, 1300 - 2245 ET

Wednesday 8 December, 2245 - 2300 ET

Story Telling

Time:

Wednesday 8 December, 2245 - 2300 ET

Conducting a Safety and Immunogenicity Study for Typhoid Conjugate Vaccine in Malawian Infants and Children

  • Dr. Nginache Nampota-Nkomba, Blantyre Malaria Project

Wednesday 8 December, 2300 ET

Late Breaker Abstracts

Time:

Wednesday 8 December, 2300 ET

Track:

Moderated by John Crump, University of Otago & Firdausi Qadri, icddr,b

  • LB300 - Twenty Years of Typhoid Genomics, Megan Carey, Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, Univeristy of Cambridge, Cambridge, UK
  • LB301 - Impact of a Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India, Seth Hoffman, Division of Infectious Diseases & Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
  • LB302 - Clinical, microbiologic, and pathologic assessment of gastro-intestinal perforations in northern Tanzania, Cristina Costales, Stanford University
  • LB303 - Modelling the subnational prevalence of antimicrobial resistance in Salmonella enterica serovars Typhi and Paratyphi A in 75 endemic countries, 1990 to 2019, Annie Brown, University of Oxford
  • LB304 - Parallel evolution of invasive Salmonella Typhimurium isolates from the Democratic Republic of Congo towards O:5 loss in the O-antigen structure, Sandra Van Puyvelde, University of Cambridge/University of Antwerp
  • LB305 - Anti-Vi IgA responses in 9- and 15-month-old children vaccinated with a typhoid conjugate vaccine in Burkina Faso, Alphonse Ouedraogo, Groupe de Recherche Action en Santé (GRAS)
Thu 9 Dec
Thursday
9
December

Thursday 9 December, 0030 - 0045 ET

Break

Time:

Thursday 9 December, 0030 - 0045 ET

Thursday 9 December, 0045 - 0145 ET

Plenary Session

Time:

Thursday 9 December, 0045 - 0145 ET

Track:

Achieving Impact: Charting the Course to Meet the Challenges Ahead

Moderated by Denise Garrett, Sabin Vaccine Institute & Jeff Stanaway, University of Washington  

Calman MacLennan, Bill & Melinda Gates Foundation 

Jason Andrews, Stanford University

Iruka Okeke, University of Ibadan

Anita Zaidi, Bill & Melinda Gates Foundation

Thursday 9 December, 0145 - 0200 ET

Closing Session

Time:

Thursday 9 December, 0145 - 0200 ET

  • Closing Remarks, Denise Garrett, Sabin Vaccine Institute